Published in
American Association for the Advancement of Science, Science Translational Medicine, 531(12), 2020
DOI: 10.1126/scitranslmed.aax2625
Links
Tools
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
Journal article published in 2020 by
Florence Coussy 
,
Rania El-Botty ,
Sophie Château-Joubert,
Ahmed Dahmani,
Elodie Montaudon,
Sophie Leboucher ,
Ludivine Morisset,
Pierre Painsec,
Laura Sourd,
Léa Huguet,
Fariba Nemati,
Jean-Luc Servely,
Thibaut Larcher ,
Sophie Vacher ,
Adrien Briaux
and other authors.
,
Rania El-Botty ,
Sophie Château-Joubert,
Ahmed Dahmani,
Elodie Montaudon,
Sophie Leboucher ,
Ludivine Morisset,
Pierre Painsec,
Laura Sourd,
Léa Huguet,
Fariba Nemati,
Jean-Luc Servely,
Thibaut Larcher ,
Sophie Vacher ,
Adrien Briaux
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Triple-negative breast cancer xenografts with BRCAness, high expression of SLFN11, and RB1 loss are highly sensitive to topoisomerase I inhibitors.